Live Breaking News & Updates on Hospital Sydney Limited

Stay updated with breaking news from Hospital sydney limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IDEAYA BIOSCIENCES, INC. : Other Events (form 8-K)

Item 8.01 Other Events

Clinical Updates

On April 23, 2023, IDEAYA Biosciences, Inc. announced interim
results from its Phase 2 clinical trial evaluating darovasertib and crizotinib
synthetic. | June 18, 2023 ....

New South Wales , United States , While The Company , Biosciences Inc , Company Annual Report On Form , Company Phase , Vincent Hospital Sydney , Exchange Commission , Clinical Updates , Data Update , Crizotinib Combination , Overall Response Rate , Disease Control Rate , Typec Meeting Supports Initiation , Potential Registrational , Adjuvant Primary , Hospital Sydney Limited , Patient Population , Private Securities Litigation Reform Act , Annual Report , Edgar Online ,

IDEAYA Biosciences : Clinical Updates - Form 8-K

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

. | June 18, 2023 ....

United States , South San Francisco , New South Wales , Yujiro Hata , Vincent Hospital Sydney , Biosciences Inc , Exchange Commission , Company Annual Report On Form , While The Company , Shoreline Court , Securities Exchange , Company Phase , Securities Exchange Act , San Francisco , Zip Code , Securities Act , Exchange Act , Data Update , Crizotinib Combination , Overall Response Rate , Disease Control Rate , Typec Meeting Supports Initiation , Potential Registrational , Adjuvant Primary , Hospital Sydney Limited , Patient Population ,

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metas

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metas
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South Australia , New South Wales , Yujiros Hata , Anthony Joshua , Mark Shackleton , Neoadjuvant Po , Werner Helicase , Darrin Beaupre , Meredith Mckean , While The Company , Exchange Commission , Kinghorn Cancer Centre , St Vincent Hospital Garvan Medical Research Institute , Head Of The Department Medical Oncology , Company Annual Report On Form , Vincent Hospital Sydney , Biosciences Inc , Skin Cancer Research , Sarah Cannon Research , Chief Medical Officer , Data Update , Crizotinib Combination , Overall Response Rate , Disease Control Rate , Progression Free Survival , Typec Meeting Supports Initiation ,

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma

Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational. | April 23, 2023 ....

South Australia , New South Wales , Neoadjuvant Po , Meredith Mckean , Anthony Joshua , Mark Shackleton , Darrin Beaupre , Yujiros Hata , Werner Helicase , While The Company , St Vincent Hospital Garvan Medical Research Institute , Vincent Hospital Sydney , Head Of The Department Medical Oncology , Exchange Commission , Biosciences Inc , Company Annual Report On Form , Kinghorn Cancer Centre , Skin Cancer Research , Sarah Cannon Research , Chief Medical Officer , Data Update , Crizotinib Combination , Overall Response Rate , Disease Control Rate , Progression Free Survival , Typec Meeting Supports Initiation ,

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into. ....

New South Wales , Yujiros Hata , Werner Helicase , Vincent Hospital Sydney , Biosciences Inc , Exchange Commission , Wrn Rd Services , Program Updates , First In Human Phase , Pol Theta Helicase , Chief Executive Officer , Crizotinib Combination Therapy , Metastatic Uveal Melanoma , Disease Control Rate , Overall Response Rate , Tumor Reduction , Study Follow Up , Progression Free Survival , Orphan Drug , Uveal Melanoma , Adjuvant Uveal Melanoma , Investigator Sponsored Trial , Hospital Sydney Limited , Clinical Trial Collaboration , Supply Agreement , Pol Theta ,